201 related articles for article (PubMed ID: 21455220)
21. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC
J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660
[TBL] [Abstract][Full Text] [Related]
22. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
24. Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Morrison CD; Chang JC; Keri RA; Schiemann WP
Cell Death Dis; 2017 Jun; 8(6):e2899. PubMed ID: 28661474
[TBL] [Abstract][Full Text] [Related]
25. c-Abl mediates angiotensin II-induced apoptosis in podocytes.
Chen X; Ren Z; Liang W; Zha D; Liu Y; Chen C; Singhal PC; Ding G
J Mol Histol; 2013 Oct; 44(5):597-608. PubMed ID: 23515840
[TBL] [Abstract][Full Text] [Related]
26. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
27. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
[TBL] [Abstract][Full Text] [Related]
28. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
Frasca F; Vigneri P; Vella V; Vigneri R; Wang JY
Oncogene; 2001 Jun; 20(29):3845-56. PubMed ID: 11439348
[TBL] [Abstract][Full Text] [Related]
30. c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage.
Udden SM; Morita-Fujimura Y; Satake M; Ikawa S
Cell Signal; 2014 Feb; 26(2):444-52. PubMed ID: 24177958
[TBL] [Abstract][Full Text] [Related]
31. Pharmacology of imatinib (STI571).
Buchdunger E; O'Reilly T; Wood J
Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
[TBL] [Abstract][Full Text] [Related]
32. Mutations in ABL kinase domain are associated with inferior progression-free survival.
Sharma P; Mohanty S; Kochupillai V; Kumar L
Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
[TBL] [Abstract][Full Text] [Related]
33. Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.
Rappa G; Anzanello F; Lorico A
Cancer Chemother Pharmacol; 2011 Apr; 67(4):919-26. PubMed ID: 20596710
[TBL] [Abstract][Full Text] [Related]
34. c-Abl phosphorylates Hdmx and regulates its interaction with p53.
Zuckerman V; Lenos K; Popowicz GM; Silberman I; Grossman T; Marine JC; Holak TA; Jochemsen AG; Haupt Y
J Biol Chem; 2009 Feb; 284(6):4031-9. PubMed ID: 19075013
[TBL] [Abstract][Full Text] [Related]
35. c-Abl neutralizes the inhibitory effect of Mdm2 on p53.
Sionov RV; Moallem E; Berger M; Kazaz A; Gerlitz O; Ben-Neriah Y; Oren M; Haupt Y
J Biol Chem; 1999 Mar; 274(13):8371-4. PubMed ID: 10085066
[TBL] [Abstract][Full Text] [Related]
36. Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.
Sears D; Luong P; Yuan M; Nteliopoulos G; Man YK; Melo JV; Basu S
Cell Death Dis; 2010 Nov; 1(11):e93. PubMed ID: 21368869
[TBL] [Abstract][Full Text] [Related]
37. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.
Wang L; Pearson K; Ferguson JE; Clark RE
Br J Haematol; 2003 Mar; 120(6):990-9. PubMed ID: 12648069
[TBL] [Abstract][Full Text] [Related]
38. Eph tumour suppression: the dark side of Gleevec.
Wang JY
Nat Cell Biol; 2006 Aug; 8(8):785-6. PubMed ID: 16880809
[No Abstract] [Full Text] [Related]
39. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Wu J; Meng F; Lu H; Kong L; Bornmann W; Peng Z; Talpaz M; Donato NJ
Blood; 2008 Apr; 111(7):3821-9. PubMed ID: 18235045
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
